Compare Tilray Brands Inc (TLRY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Zimmer Biomet Holdings Inc — how do they compare? Tilray Brands Inc trades at $4.25 (market cap $577.15M), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 31.3× Tilray Brands Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.01% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | ZBH | |
|---|---|---|
Market Cap | $577.15M | $18.05B |
Sector | Health | Health |
52-Week High | $21.00 | $104.26 |
52-Week Low | $3.88 | $79.58 |
Enterprise Value | $744.29M | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
